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Bone healing in multiple myeloma: a prospective
evaluation of the impact of first-line anti-myeloma
treatment
Myeloma cells disturb a normally balanced bone
remodeling process. This imbalance of bone metabolism
may cause osteopenic bones, focal osteolytic lesions and
clinical symptoms. 
The excess bone resorption resulting in osteolytic
lesions has traditionally been perceived as irreversible.
We investigated the potential for bone healing in a
prospective study of previously untreated multiple
myeloma (MM) patients using a five-drug bortezomib-
containing treatment regimen. 
Thirty-five newly diagnosed MM patients requiring
treatment1 were enrolled in a prospective single-center
phase-II study to evaluate the safety and efficacy of first-
line treatment with a five-drug combination (doxoru-
bicin, cyclophosphamide, bortezomib, dexamethasone
and lenalidomide; ACVDL).2 This clinical trial was
approved by The Regional Scientific Ethical Committees
for Southern Denmark and registered at
ClinicalTrials.gov (NCT01481194). EUDRACT number
2011-002751-34. All participants provided written
informed consent. The study was conducted in accor-
dance with the Declaration of Helsinki and the
International Conference on Harmonization for Good
Clinical Practice.
As a secondary endpoint of this clinical trial, the impact
of ACVDL on bone involvement in MM was evaluated in
patients who completed three or more consecutive bone
examinations at pre-specified time points.
Bone status was evaluated using low-dose computed
tomography (CT)-scan, bone single photon emission
computed tomography (SPECT)/CT-scan and serum
markers of bone turnover at baseline, after four cycles of
ACVDL (at 12 weeks), at the end-of-treatment assess-
ment (at approximately 28 weeks) and thereafter every 6
months.
Well-defined osteolytic lesions with a diameter of ≥10
mm on CT-scans were identified as target lesions at base-
line. Each target lesion was then evaluated in terms of
size and development of osteosclerosis in all consecutive
CT-scans. The presence of osteosclerosis at the edge of a
target lesion was interpreted as an early sign of healing
and classified dichotomously as being either present or
not present (Figure 1). More pronounced formation of
sclerotic bone, together with a simultaneous reduction in
the largest diameter of the osteolytic lesion by ≥30%,
was interpreted as a more advanced sign of healing
(Figure 1). 
Tracer uptake by the osteolytic target lesions by bone
SPECT was classified as decreased, equal to or increased
when compared to uninvolved bone. 
The serum bone resorption marker C-terminal telopep-
tide type-I (CTX) and the serum bone formation marker
N-terminal propeptide of procollagen I (P1NP) were meas-
ured in fasting blood samples collected in the morning.
Twenty-eight of the 35 enrolled patients completed
three or more consecutive bone examinations. Among
these, 18 patients showed at least one osteolytic lesion
that qualified as a target lesion. (Online Supplementary
Table S1).
Fifty-six osteolytic target lesions in 18 patients were
followed over time, 34% of which had increased tracer
uptake at the baseline bone-SPECT.
Sclerosis appeared in 68% of all target lesions. In 63%
of these lesions, sclerosis had already appeared at the
interim CT-scan (12 weeks after initiation of treatment).
In 24% sclerosis appeared at the end-of-treatment CT-
scan (28 weeks after initiation of treatment), while in the
remaining 13% of lesions, sclerosis appeared during the
follow-up period. Healing (size reduction) was seen in
14% of the osteolytic target lesions (Figure 2). 
Sclerosis appeared with different hematologic respons-
es; 58% with complete or very good partial remission,
24% at partial response and 18% at less than partial
response. Increased baseline bone SPECT uptake had a
tendency to be associated with development of sclerosis
(P=0.08).
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Figure 1. Sclerosis and healing.
Illustration of an osteolytic lesion
with development of sclerosis
(top) and another lesion with
development of both sclerosis
and size-reduction (bottom). (A)
Baseline (B) After treatment.
Of the patients with osteolytic target lesions, 72% had
at least one lesion with development of sclerosis, while
56% had target lesions both with development of sclero-
sis and lesions with no response. Thirty-nine percent of
the patients with osteolytic target lesions had at least one
lesion with healing (size reduction) (Online
Supplementary Table S2).
The serum levels of the bone formation marker P1NP
showed a significant decrease from baseline to interim
assessment (P<0.01), before increasing from the interim
to end-of-treatment assessment (P<0.001) (Figure 3A).
Serum P1NP levels were significantly higher at end of
treatment than at any other time points. The serum level
of the bone resorption marker CTX was higher at base-
line than at any subsequent measurement in the majority
of patients (Figure 3B). 
In recent years, the introduction of several novel agents
for the treatment of MM has improved patients’ survival.3
In order to improve quality of life it is also important to
control the bone lesions and if possible revert bone dam-
age that has already occurred. 
In addressing the impact of a five-drug bortezomib-
containing treatment on bone healing in MM, we found
development of a rim of sclerosis in the osteolytic lesions
of the majority of the patients and that some osteolytic
lesions also showed more profound signs of healing.
While sclerosis was observed in all the lesions in a small
number of patients, a heterogeneous response was found
in individual patients in general, with some lesions show-
ing sclerosis or healing and some showing no response.
We found that 72% of the patients with osteolytic tar-
get lesions developed bone sclerosis. This is far greater
than the 18% reported from a retrospective study of MM
patients receiving various bortezomib-containing regi-
mens when also taking into account that the study of
Schulze et al. included patients without osteolytic
lesions.4 The discrepancy may be due to the fact that only
14% of the patients in the study by Schulze et al.
received first-line treatment.4 It is likely that osteolytic
lesions that have existed for a long time may lose their
potential for healing. Furthermore, only osteolytic lesions
with a minimum size of 10 mm were considered  in our
study. It is unclear whether the size of a lesion plays a
role in its healing potential.
We found signs of sclerosis and healing in patients with
all levels of responses to anti-myeloma treatment, as pre-
viously reported.4 Bone sclerosis often appeared before
the best hematologic response was achieved. In some
patients sclerosis or healing was seen during follow-up,
indicating improved bone metabolism during the period
of remission. 
Increased tracer uptake by bone SPECT was seen more
frequently, albeit not significantly so, in lesions that
developed osteosclerosis. This observation suggests that
the healing potential of an osteolytic lesion may be
dependent on the degree of perturbation of the microen-
vironment at the time of treatment initiation. Andersen
et al. have shown that myeloma cells disrupt a micro-
anatomical structure; the bone remodeling compartment
that appears to be of crucial importance for maintaining
the integrity of bone.5 The extent of local disruption of
the bone remodeling compartments may influence the
capacity to initiate new bone formation at a later point in
time. The suggested correlation between increased base-
line bone SPECT activity and subsequent formation of
sclerosis in osteolytic lesions supports the assumption
that if the capacity to form new bone locally has been
totally eliminated the chance of recovery is poor.6
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Figure 2. Sclerosis and healing
of osteolytic target lesions.
Time of development of sclerosis
or healing of the 56 osteolytic
target lesions observed in 18
patients. The number is the
patients’ identification number
and each patient had between
one and five target lesions. The
circles illustrate the target
lesions and the color of the cir-
cles represent the status at dif-
ferent time points. Each row
shows different time points from
baseline to the interim assess-
ment, end of treatment and fol-
low-up. Boxes without circles
indicate missing scans. Note the
variability of responses in indi-
vidual patients. Open circles: no
sclerosis. Gray circles: sclerosis.
Black circles: healing. X: osteolyt-
ic lesions excluded due to verte-
broplasty. EoT: end of treatment;
FU1, 2, 3: follow-up assess-
ments 6, 12 and 18 months
after end of treatment. 
We found an increase of the bone formation marker
P1NP during treatment, with a peak at the end of treat-
ment when the patients had obtained the maximum
response to anti-myeloma therapy. The bone formation
at this point in time may compensate for the increased
bone loss that occurred at the time of diagnosis. Even
though we were unable to determine to what extent the
increased bone formation was driven by a specific com-
ponent of the therapy (bortezomib), the result did show
that treatment can improve bone formation in MM, as
previously reported.7 The levels of CTX, the serum mark-
er of bone resorption, dropped rapidly following initia-
tion of anti-myeloma treatment, which was in agreement
with previous studies.8, 9 In our study, serum CTX levels
remained suppressed following initiation of anti-myelo-
ma treatment, with the inclusion of zoledronate for the
majority of patients. Decreased values of bone resorption
markers were recently reported in MM patients receiving
VTD (bortezomib, thalidomide, dexamethasone) consol-
idation after autologous stem cell transplantation, but
without bisphosphonate treatment.10 This observation
supports the view that effective treatment of MM itself is
a key factor in the control of excessive bone resorption.
Thus, it is reasonable to suggest that both anti-myeloma
treatment and bisphosphonates play a role in the control
of excessive bone resorption in MM. The combination of
specific drugs used to treat myeloma may have signifi-
cance for the effect on bone, since bortezomib has previ-
ously been reported to increase bone formation evaluated
by serum bone markers in responding patients,11,12 unlike
lenalidomide, which had no influence on the effect.8 The
present trial included both bortezomib and lenalidomide
in a combined treatment (Online Supplementary
Methods) as an attempt to optimize disease control. 
This prospective study showed that osteolytic lesions
may, at the very least, be partially reversible in the major-
ity of responding patients. Nevertheless, our data also
showed intra-patient variation with respect to re-induc-
tion of bone formation in the osteolytic lesions. As a con-
sequence, the degree of destruction of the microenviron-
ment within the individual osteolytic lesion may have
implications for any possibility of achieving healing of
bone lesions. 
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